Mechano growth factor E peptide promotes osteoblasts proliferation and bone-defect healing in rabbits.
Deng. Moyuan M; Zhang. Bingbing B; Wang. Ke K; Liu. Feng F; Xiao. Hualiang H; Zhao. Jianhua J; Liu. Peng P; Li. Yuxiao Y; Lin. Fuchun F; Wang. Yuanliang Y
Key Findings
- MGF‑Ct24E boosted osteoblast proliferation 1.4‑fold compared to IGF‑1 in cell culture
- The peptide pushed cells into the S and G2/M phases and activated the MAPK‑Erk1/2 pathway
- In rabbits with a 5 mm radius bone gap, daily injections of 57 µg/kg for five days significantly increased radiographic and histologic healing versus no treatment
Practical Outcomes
- The data suggest MGF‑Ct24E could be explored as a supplement to speed fracture repair, but results are limited to rabbits and short‑term dosing. For biohackers, any human use would be experimental, requiring careful dose translation and safety monitoring. Until human trials are done, the peptide remains a promising research candidate rather than a ready‑to‑use protocol.
Summary
A short piece of the mechano growth factor protein (MGF‑Ct24E) helped bone‑building cells grow faster and improved healing of a broken bone in rabbits, working better than regular IGF‑1 at the doses tested.
Abstract
To assess the potential efficacy of mechano growth factor (MGF) for bone injury, we firstly investigated the effects of growth factors, including MGF, its E peptide (a short 24-amino acid C-terminal peptide, MGF-Ct24E), and insulin-like growth factor 1(IGF-1) on MC3T3-E1 osteoblast-like cell proliferation. MGF-Ct24E had the highest pro-proliferation activity among three growth factors, which was 1.4 times greater than that of IGF-1. Moreover, MGF-Ct24E promoted cell proliferation by inducing cell cycle arrest in the S and G(2)/M phase of the cell cycle, but also mainly by the activation of the MAPK-Erk1/2 pathway. In vivo, a 5-mm segmental bone defect in the radius of 27 rabbits was treated with MGF-Ct24E by two doses (28.5 and 57 μg /kg body weight) vs. non-growth factor injection for five consecutive days postoperatively. The cumulative rate of radiographically healed defects and histological scores of bone defect-healing revealed a statistical difference between high-dose treatment and non treatment (p < 0.01), which showed the treatment promoted defect healing. This report is the first to demonstrate that MGF-Ct24E possesses positive effects on osteoblast proliferation and bone-defect healing, suggesting a new strategy in fracture healing.
Study Information
pubmed
2010
2010-11-06T00:00:00.000Z
10.1007/s00264-010-1141-2
50
25